Comments on the guidelines for the European Society of Cardiology (ESC) on the diagnosis and treatment of acute and chronic heart failure;Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Behandlung der akuten und chronischen Herzinsuffizienz

Kardiologe

Volumn 7, Issue 2, 2013, Pages 105-114

  Hasenfuss G ^a,h   Anker, S ^b   Bauersachs, J ^c   Bohm M ^d   Hoppe, U C ^e   Pieske, B ^f   Von Scheidt, W ^g   Wachter, R ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF SALZBURG   (Austria)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g KLINIKUM AUGSBURG   (Germany)

^h DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Aldosterone antagonists; Cardiac resynchronization therapy; Iron replacement therapy; Resynchronization strategies; Sinus node inhibitor

Indexed keywords

ALDOSTERONE ANTAGONIST; IRON; IVABRADINE;

ACUTE HEART FAILURE; AORTA STENOSIS; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR THERAPEUTIC DEVICE; DISEASE SEVERITY; EARLY INTERVENTION; HEALTH PROGRAM; HEART FAILURE; HUMAN; MITRAL VALVE REGURGITATION; PATIENT EDUCATION; PRACTICE GUIDELINE; TREATMENT INDICATION;

EID: 84880781202     PISSN: 18649718     EISSN: 18649726     Source Type: Journal    
DOI: 10.1007/s12181-013-0491-6     Document Type: Article

References (24)

1. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012. Eur Heart J 33:1787-1847
2. ESC Guidelines for the Diagnose and Treatment of Acute and Chronic Heart Failure 2012. Eur J Heart Fail 14:803-869
3. Meta-analysis Global Group in Chronic Heart Failure (MAGIC) (2012) The survival of patients with heart failure with preserved and reduced left ventricluar ejection fraction: patient data meta-analysis. Eur Heart J 33:1750-1757
4. Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11-21
5. Swedberg K, Komajda M, Bohm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 376:875-885
6. Taylor AL, Zische S, Yancy C et al (2004) Combination of iosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351:2049-2057
7. Tavazzi L, Maggioni AP, Marchioli R et al (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372:1223-1230
8. Kiekshus J, Apetrei E, Barrios V et al (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248-2261
9. Tavazzi L, Maggioni AP, Marchioli R et al (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372:1231-1239
10. Massie BM, Carson PE, McMurray JJ et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456-2467
11. Moss AJ, Hall WJ, Cannom DS et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329-1338
12. Tang AS, Wells GA, Talajic M et al (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363:2385-2395
13. Sipahi I, Carrigan TP, Rowsland DY et al (2011) Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med 171:1354-1462
14. O'Connor CM, Jiang W, Kuchibhatla M et al (2010) Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 56:692-699
15. Anker SD, Comin Colet J, Filippatos G et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436-2448
16. Gheorghiade M, Konstam MA, Burnett JC Jr et al (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297:1332-1343
17. Thiele H, Zeymer U, Neumann FJ et al (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367:1287-1296
18. Velazquez EJ, Lee KL, Deja MA et al (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 364:1607-1616
19. De Bruyne B, Pijls NH, Kalesan B et al (2012) Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 367:991-1001
20. Slaughter MS, Rogers JG, Milano CA et al (2009) Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361:2241-2251
21. Feldman T, Kar S, Rinaldi M et al (2009) Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 54:686-694
22. O'Connor CM, Whellan DJ, Lee KL et al (2009) Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301:1439-1450
23. Edelmann F, Gelbrich G, Düngen HD et al (2011) Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 58:1780-1791
24. Inglis SC, Clark RA, McAlister FA et al (2011) Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: abridged cochrane review. Eur J Heart Fail 13:1028-1040